Orexigen Therapeutics (NASDAQ: OREX) issued the following statement regarding the termination of the Light Study a cardiovascular (CV) outcomes trial ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE